The role of fibrotic markers in risk stratification of atrial fibrillation in patients with metabolic syndrome
https://doi.org/10.18705/2311-4495-2016-3-3-17-25
Abstract
Objective. To evaluate serum galectin 3, aldosterone in patients with metabolic syndrome (MS) and atrial fibrillation (AF) and to reveal the correlation of these markers of fibrosis with risk factors of AF. Design and methods. We examined 100 patients with MS (50 with paroxysmal or persistent AF and 50 without arrhythmia) and 50 healthy persons. Serum galectin 3 and aldosterone were measured by ELISA method, ECHO cardiography was performed. Results. Serum aldosterone concentration in MS and AF group was higher than in healthy controls (202,2 ± 82,5 and 98,4 ± 51,8 pg/ml; р < 0,001) and higher than in the MS group without AF (202,2 ± 82,5 and 150,3 ± 72,2 pg/ml; р < 0,001). Serum galectin 3 in patients with MS and AF was higher, than in patients with MS without arrhythmia and much more higher than galectin 3 in healthy persons (0,72 [0,44; 1,36], 0,44 [0,42; 1,22] and 0,32 [0,28; 0,42] ng/ml; р < 0,01). Positive correlation between serum aldosterone and serum galectin 3 was reveal (r = 0,509, p < 0,001). Conclusion. Markers of fibrosis serum galectin 3 and serum aldosterone in patients with atrial fibrillation and metabolic syndrome was higher than in patients with the metabolic syndrome, without this arrhythmia and higher than in healthy persons. The correlation between serum aldosterone, serum galectin 3 and remodeling of left atrium was reveal. The markers of fibrosis (aldosteron, galectin 3) were associated with risk of AF in patients with MS.
About the Authors
Valeriy A. Ionin
Pavlov First Saint Petersburg State Medical University
Russian Federation
Russian Federation
Elena I. Baranova
Pavlov First Saint Petersburg State Medical University; Almazov Federal North-West Medical Research Centre
Russian Federation
Russian Federation
References
1. Savelieva I., Camm J. Update on atrial fibrillation: part I. Clin. Cardiol. 2008; 31(2): 55-62.
2. Chamberlain A.M., Agarwal S.K., Ambrose M., et al. Metabolic syndrome and incidence of atrial fibrillation among blacks and whites in the Atherosclerosis Risk in Communities (ARIC) Study. Am Heart J. 2010; 159(5): 159-164.
3. De Boer R.A. et al. Predictive value of plasma galectin-3 levels in heart failure with reduced and preserved ejection fraction. Ann Med. 2011; 43(1): 60-68.
4. Jennifer E.H. et al. Galectin 3 and incident atrial fibrillation in the community. Am. Heart J. 2014; 167: 729-734.
5. Nattel S., Burstein B., Dobrev D. Atrial remodeling and atrial fibrillation: mechanisms and implications. Circ Arrhythmia Electrophysiol. 2008; 1(1): 62-73.
6. Menezes A.R., Lavie C.J., Di Nicolantonio J.J. Atrial fibrillation in the 21st century: a current understanding of risk factors and primary prevention strategies. Mayo Clin Proc. 2013; 88(4): 394-409.
7. Akoum N., Marrouche N. Assessment and impact of cardiac fibrosis on atrial fibrillation. Curr Cardiol Rep. 2014; 16(8): 518.
8. Beinart R. et al. Сardiac magnetic resonance T1 mapping of left atrial myocardium. Heart Rhythm. 2013; 10(9): 1325-1331.
9. Weber K.T. et al. Aldosteronism in heart failure: a proinflammatory/fibrogenic cardiac phenotype. Search for biomarkers and potential drug targets. Curr Drug Targets. 2003; 4(6): 505-516.
10. Yen-Hung L. et al. Aldosterone induced galectin-3 secretion in vitro and in vivo: from cells to humans. PLoS One. 2014; 9(9): e95254.
11. Yalcin M.U. et al. The association of serum galectin-3 levels with atrial electrical and structural remodeling. J Cardiovasc Electrophysiol. 2015; 26(6): 635-640.
Review
For citations:
Ionin V.A., Baranova E.I. The role of fibrotic markers in risk stratification of atrial fibrillation in patients with metabolic syndrome. Translational Medicine. 2016;3(3):17-25. (In Russ.) https://doi.org/10.18705/2311-4495-2016-3-3-17-25
Views:
628
Email this article 